Literature DB >> 1828135

Extracellular and intracellular activities of clarithromycin used alone and in association with ethambutol and rifampin against Mycobacterium avium complex.

N Rastogi1, V Labrousse.   

Abstract

Mycobacterium avium complex bacteria are opportunistic human pathogens, and their chemotherapy remains a challenge since these organisms are resistant to a majority of routine antituberculous drugs. Recently, a wide range of new macrolide antibiotics has been developed, among which the drug clarithromycin appears to have a selective action against M. avium bacteria. In the present study, we have investigated the action of clarithromycin alone (MIC and MBC determinations) and in association with the routine antimycobacterial drugs ethambutol and rifampin at sublethal concentrations (1 micrograms/ml; below concentrations obtainable in human serum) against M. avium. Our viable count data showed that clarithromycin was bactericidal against all 10 strains of M. avium studied and that its activity was enhanced by ethambutol (in 8 of 9 strains) and rifampin (in 3 of 9 strains). The use of all three drugs in association resulted in higher bactericidal effects than found with any of the drugs used alone or in two-drug combinations in seven of nine strains. The bactericidal effects of various drugs used alone and in combination at concentrations obtainable in human serum were investigated against the type strain ATCC 15769 by using 7H9 broth and BACTEC radiometry (extracellular action) and a J-774 macrophage cell line (intracellular action). A good agreement between the extracellular and intracellular activities was found. Electron microscopy using a ruthenium red cytochemical staining of the bacteria showed that clarithromycin disorganized the outer wall layer and the cytoplasmic membrane in the mycobacterial cell envelope and resulted in formation of large vacuoles inside the cytoplasm, with solubilization of ribosomal structures and consequent plasmolysis. Its association with ethambutol and rifampin resulted in more drastic alterations in the bacterial morphology than were seen with any of the drugs used alone, leading to the removal of the bacterial outer layer, homogenization of cytoplasm, complete cell lysis, and formation of ghosts.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1828135      PMCID: PMC245033          DOI: 10.1128/AAC.35.3.462

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  25 in total

1.  Evidence that the capsule around mycobacteria grown in axenic media contains mycobacterial antigens: implications at the level of cell envelope architecture.

Authors:  N Rastogi; R Hellio
Journal:  FEMS Microbiol Lett       Date:  1990-07       Impact factor: 2.742

2.  Action of 1-isonicotinyl-2-palmitoyl hydrazine against the Mycobacterium avium complex and enhancement of its activity by m-fluorophenylalanine.

Authors:  N Rastogi; K S Goh
Journal:  Antimicrob Agents Chemother       Date:  1990-11       Impact factor: 5.191

3.  In vitro and in vivo activities of macrolides against Mycobacterium leprae.

Authors:  S G Franzblau; R C Hastings
Journal:  Antimicrob Agents Chemother       Date:  1988-12       Impact factor: 5.191

4.  Activity of five fluoroquinolones against Mycobacterium avium-intracellulare complex and M. xenopi.

Authors:  N Rastogi; K S Goh; H L David
Journal:  Ann Inst Pasteur Microbiol       Date:  1988 Mar-Apr

5.  In-vitro activity of erythromycin against atypical mycobacteria.

Authors:  A Molavi; L Weinstein
Journal:  J Infect Dis       Date:  1971-02       Impact factor: 5.226

6.  Pyrazinamide is not effective against intracellularly growing Mycobacterium tuberculosis.

Authors:  N Rastogi; M C Potar; H L David
Journal:  Antimicrob Agents Chemother       Date:  1988-02       Impact factor: 5.191

7.  Studies on the mechanisms of the synergistic effects of ethambutol and other antibacterial drugs on Mycobacterium avium complex.

Authors:  S E Hoffner; G Källenius; A E Beezer; S B Svenson
Journal:  Acta Leprol       Date:  1989

8.  In vitro and in vivo activities of clarithromycin against Mycobacterium avium.

Authors:  P B Fernandes; D J Hardy; D McDaniel; C W Hanson; R N Swanson
Journal:  Antimicrob Agents Chemother       Date:  1989-09       Impact factor: 5.191

9.  Drug susceptibility testing in tuberculosis: a comparison of the proportion methods using Lowenstein-Jensen, Middlebrook 7H10 and 7H11 agar media and a radiometric method.

Authors:  N Rastogi; K S Goh; H L David
Journal:  Res Microbiol       Date:  1989 Jul-Aug       Impact factor: 3.992

10.  Comparative antimycobacterial activities of difloxacin, temafloxacin, enoxacin, pefloxacin, reference fluoroquinolones, and a new macrolide, clarithromycin.

Authors:  E A Gorzynski; S I Gutman; W Allen
Journal:  Antimicrob Agents Chemother       Date:  1989-04       Impact factor: 5.191

View more
  48 in total

Review 1.  Antimicrobial susceptibility testing, drug resistance mechanisms, and therapy of infections with nontuberculous mycobacteria.

Authors:  Barbara A Brown-Elliott; Kevin A Nash; Richard J Wallace
Journal:  Clin Microbiol Rev       Date:  2012-07       Impact factor: 26.132

2.  Use of Mono Mac 6 human monocytic cell line and J774 murine macrophage cell line in parallel antimycobacterial drug studies.

Authors:  E L Wright; D C Quenelle; W J Suling; W W Barrow
Journal:  Antimicrob Agents Chemother       Date:  1996-09       Impact factor: 5.191

3.  Activities of clarithromycin, ofloxacin, and clarithromycin plus ethambutol against Mycobacterium simiae in murine model of disseminated infection.

Authors:  G Valero; F Moreno; J R Graybill
Journal:  Antimicrob Agents Chemother       Date:  1994-11       Impact factor: 5.191

4.  A bone marrow-derived murine macrophage model for evaluating efficacy of antimycobacterial drugs under relevant physiological conditions.

Authors:  P S Skinner; S K Furney; M R Jacobs; G Klopman; J J Ellner; I M Orme
Journal:  Antimicrob Agents Chemother       Date:  1994-11       Impact factor: 5.191

5.  Efficacy of granulocyte colony-stimulating factor and RU-40555 in combination with clarithromycin against Mycobacterium avium complex infection in C57BL/6 mice.

Authors:  T Lazard; C Perronne; Y Cohen; J Grosset; J L Vilde; J J Pocidalo
Journal:  Antimicrob Agents Chemother       Date:  1993-04       Impact factor: 5.191

6.  Activity of subinhibitory concentrations of dapsone alone and in combination with cell-wall inhibitors against Mycobacterium avium complex organisms.

Authors:  N Rastogi; K S Goh; V Labrousse
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1993-12       Impact factor: 3.267

7.  Activities of fluoroquinolone, macrolide, and aminoglycoside drugs combined with inhibitors of glycosylation and fatty acid and peptide biosynthesis against Mycobacterium avium.

Authors:  W W Barrow; E L Wright; K S Goh; N Rastogi
Journal:  Antimicrob Agents Chemother       Date:  1993-04       Impact factor: 5.191

8.  Clarithromycin therapy of experimental Treponema pallidum infections in hamsters.

Authors:  J Alder; K Jarvis; M Mitten; N L Shipkowitz; P Gupta; J Clement
Journal:  Antimicrob Agents Chemother       Date:  1993-04       Impact factor: 5.191

9.  Roxithromycin alone and in combination with either ethambutol or levofloxacin for disseminated Mycobacterium avium infections in beige mice.

Authors:  L E Bermudez; P Kolonoski; L S Young
Journal:  Antimicrob Agents Chemother       Date:  1996-04       Impact factor: 5.191

10.  Efficacies of liposome-encapsulated clarithromycin and ofloxacin against Mycobacterium avium-M. intracellulare complex in human macrophages.

Authors:  C O Onyeji; C H Nightingale; D P Nicolau; R Quintiliani
Journal:  Antimicrob Agents Chemother       Date:  1994-03       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.